Hexagon Capital Partners LLC Purchases 176 Shares of Edwards Lifesciences Co. (NYSE:EW)

Hexagon Capital Partners LLC raised its position in Edwards Lifesciences Co. (NYSE:EW) by 33.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 703 shares of the medical research company’s stock after acquiring an additional 176 shares during the period. Hexagon Capital Partners LLC’s holdings in Edwards Lifesciences were worth $67,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank acquired a new position in Edwards Lifesciences during the 4th quarter valued at about $648,540,000. Brown Advisory Inc. increased its holdings in shares of Edwards Lifesciences by 20.1% during the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after acquiring an additional 3,048,274 shares in the last quarter. CIBC Private Wealth Group LLC raised its position in shares of Edwards Lifesciences by 197.0% in the 4th quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock valued at $262,815,000 after purchasing an additional 2,286,119 shares during the last quarter. AustralianSuper Pty Ltd purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $168,519,000. Finally, Sands Capital Management LLC boosted its stake in Edwards Lifesciences by 34.6% in the 4th quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock worth $465,407,000 after purchasing an additional 1,567,526 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EW has been the topic of several research analyst reports. Wells Fargo & Company boosted their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Citigroup upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $98.00 to $105.00 in a research report on Wednesday, May 22nd. StockNews.com raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Thursday, June 27th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Finally, Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $95.06.

Edwards Lifesciences Trading Down 2.3 %

Shares of EW stock opened at $90.23 on Tuesday. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The firm has a market capitalization of $54.37 billion, a P/E ratio of 38.89, a PEG ratio of 3.38 and a beta of 1.11. The stock’s fifty day moving average is $87.85 and its two-hundred day moving average is $85.37. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. Research analysts expect that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Scott B. Ullem sold 7,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total transaction of $622,050.00. Following the transaction, the chief financial officer now owns 19,074 shares in the company, valued at $1,636,549.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CFO Scott B. Ullem sold 5,625 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $90.45, for a total value of $508,781.25. Following the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,764,242.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,250 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total value of $622,050.00. Following the sale, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at approximately $1,636,549.20. The disclosure for this sale can be found here. Insiders sold 119,849 shares of company stock worth $10,579,038 over the last ninety days. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.